X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IP Explained: Why patents are so critical to biopharmaceutical innovation

By Tom Wilbur  |    April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...   Read More

New report: Using march-in authority would jeopardize U.S. innovation

By Tom Wilbur  |    March 19, 2019
In 1980, Congress passed the Small Business Patent Procedures Act, better known as the Bayh-Dole Act, which created a uniform framework for transferring government-funded research into useful...   Read More

Special 301 submission calls for a level playing field for American innovators

By Megan Van Etten  |    March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...   Read More

Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement

By Douglas Petersen  |    February 27, 2019
There are a lot of misconceptions and inaccuracies going around about the United States-Mexico-Canada Agreement (USMCA) and its implications for biopharmaceutical innovation and medicine prices....   Read More

PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation

By Douglas Petersen  |    November 2, 2018
International trade is critical to delivering life-saving and life-enhancing medicines in the global economy, which is why PhRMA addresses several discriminatory foreign government practices in...   Read More

Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines

By Andrew Powaleny  |    July 25, 2018
In today’s new era of medicine, America’s biopharmaceutical companies are conducting some of the most complex and difficult research in the world to develop innovative treatments for patients.   Read More

Event next week: Supporting the next generation of lifesaving medicines

By Andrew Powaleny  |    July 12, 2018
The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more...   Read More

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

By Nicole Longo  |    June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...   Read More

Supreme Court decisions in two cases pave way for IPR reforms

By Nicole Longo  |    May 31, 2018
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...   Read More

To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements

By Jay Taylor  |    May 10, 2018
May is World Trade Month, when we celebrate the many American companies exporting products around the world, and growing opportunities here in the U.S.   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates